New targeted radiation therapy shows promise for advanced liver cancer
NCT ID NCT06852820
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 30 times
Summary
This study tests a drug called 177Lu-PSMA-617 in people with liver cancer that has spread and shows a specific marker (PSMA) on scans. The goal is to see if the drug is safe and can shrink tumors. About 10 adults who have already tried one standard treatment will receive this targeted radiation therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center, Seidman Cancer Center
RECRUITINGCleveland, Ohio, 44106, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.